Myelodysplastic syndromes: where do we go from here?

Affiliations

Comment

Hetty E Carraway et al. Oncology (Williston Park). 2011 May.

. 2011 May;25(6):492-3.

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.

No abstract available

Comment on

When to treat myelodysplastic syndromes.
Akhtari M. Akhtari M. Oncology (Williston Park). 2011 May;25(6):480-6. Oncology (Williston Park). 2011. PMID: 21717901 Review.

1. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood. 2003;102:394–403. - PubMed
1. Scott B, Wells D, Deeg J, et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplanation outcome in patients with myelodysplastic syndrome. Blood. 2008;112:2681–6. - PMC - PubMed
1. Alhan C, Westers T, Van de Loosdrecht A, et al. Flow cytometric score correlates with clinical response to azacitidine in intermediate 2 and high risk myelodysplastic syndrome patients [abstract 441].. American Society of Hematology Annual Meeting and Exposition; Orlando, Fla.. 2010 Dec 4-7.
1. Itzykson R, Kosmider O, Fenaux P, et al. Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS [abstract 439].. American Society of Hematology Annual Meeting and Exposition; Orlando, Fla.. 2010 Dec 4-7.
1. Paschka P, Schlenk R, Dohner K, et al. IDH1 and IDH2 mutations are frequently genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:XX. - PubMed